Idiopathic Pulmonary Fibrosis: How to Recognize and When to Refer

The 2 novel vaccine candidates each combine a Sanofi licensed influenza vaccine with the Novavax adjuvanted recombinant COVID-19 vaccine.

William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.

Many unvaccinated adults reported intent to get vaccinated, according to early season estimates released in MMWR.

In our latest podcast episode, Njira Lugogo, MD, discusses NAVIGATOR data she presented at ATS 2022 that showed clinical responses to treatment with tezepelumab.

Insights on how to manage the "triple threat" of flu, RSV, and COVID-19 this season.

Your daily dose of the clinical news you may have missed.